American Oncology Network (AON) announced the appointment of Stephen "Fred" Divers, MD, a medical oncologist with Genesis Cancer and Blood Institute, as its new chief medical officer.
Fort Myers, Florida — American Oncology Network (AON) announced today, May 18, that Stephen "Fred" Divers, a medical oncologist with Genesis Cancer and Blood Institute, will serve as its new chief medical officer (CMO).
As CMO, Divers will play a vital role in furthering AON’s mission, providing leadership, strategy, and vision around practice transformation ensuring that its clinical model addresses patient needs. In addition to his new role as CMO, Dr. Divers will continue as AON Advisory Board Chairman and see patients at Genesis Cancer and Blood Institute.
“We are thrilled to announce Dr. Divers as our CMO,” said Todd Schonherz, chief executive officer, AON. “Since AON’s inception and as chairman of the AON Advisory Board, Dr Divers has been instrumental in leading the charge on ensuring patients have ready access to affordable, high quality cancer care in their local communities."
Politics vs Science: The Future of US Public Health
February 4th 2025On this episode of Managed Care Cast, we speak with Perry N. Halkitis, PhD, MS, MPH, dean of the Rutgers School of Public Health, on the public health implications of the US withdrawal from the World Health Organization and the role of public health leaders in advocating for science and health.
Listen
Bridging Care Gaps With a Systemwide Value-Based Care Strategy
March 29th 2025Mapping care management needs by defining patient populations and then stratifying them according to risk and their needs can help to spur the transformation of a siloed health care system into an integrated system that is able to better provide holistic, value-based care despite the many transitions that continue among hospital, primary, specialty, and community care environments.
Read More
Understanding Primary and Secondary Nonadherence to Chronic Oral Medication
March 28th 2025Medication nonadherence to oral anticoagulants and oral anti–prostate cancer medication has been scrutinized through new research conducted among patients and health care providers and presented by the American Medical Group Association at its 2025 annual meeting, held March 26-29 in Grapevine, Texas.
Read More